Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) – Zacks Research reduced their Q1 2025 earnings per share (EPS) estimates for Vertex Pharmaceuticals in a note issued to investors on Thursday, January 23rd. Zacks Research analyst R. Department now expects that the pharmaceutical company will post earnings of $3.51 per share for the quarter, down from their prior forecast of $3.82. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($1.90) per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q2 2025 earnings at $3.76 EPS.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. The firm had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.67 earnings per share.
Check Out Our Latest Stock Analysis on VRTX
Vertex Pharmaceuticals Stock Down 0.7 %
Shares of NASDAQ:VRTX opened at $440.68 on Monday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average price is $434.90 and its 200 day moving average price is $463.98. The stock has a market cap of $113.49 billion, a price-to-earnings ratio of -221.45, a price-to-earnings-growth ratio of 2.20 and a beta of 0.40. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88.
Institutional Trading of Vertex Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in the business. Northwest Investment Counselors LLC purchased a new position in Vertex Pharmaceuticals in the 3rd quarter worth approximately $25,000. Highline Wealth Partners LLC bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $27,000. Dunhill Financial LLC raised its stake in Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 24 shares in the last quarter. Brown Lisle Cummings Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at approximately $30,000. Finally, Legacy Investment Solutions LLC bought a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $33,000. 90.96% of the stock is owned by hedge funds and other institutional investors.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- Energy and Oil Stocks Explained
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- What Does the Future Hold for Eli Lilly?
- How to Invest in Small Cap Stocks
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.